|Mr. Ian C. Read||Exec. Chairman||5.03M||13.86M||1954|
|Mr. Frank A. D'Amelio||CFO & EVP of Global Supply, Bus. Operations and Manufacturing Operations of Pfizer Global Supply||2.67M||3.84M||1958|
|Dr. Mikael Dolsten||Chief Medical Officer and Global Pres of Worldwide R&D and Medical||2.65M||3.84M||1959|
|Mr. John D. Young||Chief Bus. Officer||2.67M||906.22k||1965|
|Ms. Loretta V. Cangialosi||Sr. VP, Controller & Principal Accounting Officer||N/A||N/A||N/A|
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immunicum AB (publ); Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Leap Therapeutics, Inc.; Nektar Therapeutics; Zenith Epigenetics Ltd., and Kineta Immuno-Oncology, LLC, as well as development agreement with Antares Pharma, Inc. It also has a collaboration agreement with Aileron Therapeutics, Inc. The company was founded in 1849 and is headquartered in New York, New York.
Pfizer Inc.’s ISS Governance QualityScore as of January 1, 2019 is 1. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 1; Compensation: 3.